clients, partners and patients to develop new treatments for NASH, diabetes and obesity.

Science Driven Therapeutically Focused

Delivering on the Potential of Innovative Therapeutics for Metabolic Diseases

Advise • Advance • Achieve

Clinical Development and Regulatory Strategy + State-of-the-Art Clinical Facility + Full Scope CRO Services + Global Scientific Network

ProSciento Services

Specialty consulting services for clinical development, regulatory strategy and licensing.
State-of-the-art clinical research facilities for metabolic drug and device clinical trials.
Full scope, comprehensive multi-site services to support metabolic clinical research programs.
Global network of partners connecting our clients to the most innovative research methods.


August 6, 2018

ProSciento Expands Executive Team, Appoints Brian Mooney Chief Operating Officer Read More »

June 21, 2018

ProSciento and Tidepool Collaborate to Integrate Diabetes Device Data Aggregation Platform into Clinical Trials Read More »


View Our Presentation


March 1, 2018

Pathophysiology of Cardiovascular Disease in Diabetes Mellitus Read More »

January 19, 2018

Single Dose Euglycemic Clamp Studies Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between MK-1293 Insulin Glargine and Originator Insulin Glargine (Lantus) in Type 1 Diabetes and Healthy Subjects Read More »

December 18, 2017

FDA approves Ozempic to improve glycemic control in adults with T2D Read More »

Stay Connected

Would you like to receive updates from ProSciento?

I'm interested in receiving: